In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J seeks dismissal of US case claiming kickbacks to Omnicare

This article was originally published in Scrip

Executive Summary

Johnson & Johnson is aggressively fighting claims in a whistleblower lawsuit, joined by the US Department of Justice and several states, which charges that J&J paid tens of millions of dollars in kickbacks between 1999 and 2004 to induce Omnicare, a provider of pharmacy services, to boost use of J&J medicines such as the antipsychotic Risperdal (risperidone) to its nursing home clients. J&J argues that the alleged kickbacks were standard, legal contracting arrangements pertaining to increased rebates for obtaining market share, and are allowable under federal law.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts